4.7 Article

Cardiovascular dysregulation of miR-17-92 causes a lethal hypertrophic cardiomyopathy and arrhythmogenesis

期刊

FASEB JOURNAL
卷 27, 期 4, 页码 1460-1467

出版社

FEDERATION AMER SOC EXP BIOL
DOI: 10.1096/fj.12-221994

关键词

microRNA; mouse model; connexin43; Pten

资金

  1. New York University (NYU) Cancer Institute Cancer Center [5P30CA016087-32]
  2. NYU-Health and Hospitals Corp.
  3. Clinical and Translational Science Institute
  4. National Center for Advancing Translational Sciences/U.S. National Institutes of Health (NIH) [UL1 TR000038]
  5. NIH/National Center for Research Resources [1ULIRR029893]
  6. Liddy Shriver Sarcoma Initiative
  7. LMS Direct Research Foundation
  8. Edna's Foundation of Hope
  9. NIH [R01HL82727, S10RR026881, R01HL106063, R01HL107953]

向作者/读者索取更多资源

MicroRNA cluster miR-17-92 has been implicated in cardiovascular development and function, yet its precise mechanisms of action in these contexts are uncertain. This study aimed to investigate the role of miR-17-92 in morphogenesis and function of cardiac and smooth muscle tissues. To do so, a mouse model of conditional overexpression of miR-17-92 in cardiac and smooth muscle tissues was generated. Extensive cardiac functional studies identified a dose-dependent induction of dilated, hypertrophic cardiomyopathy, and arrhythmia inducibility in transgenic animals, which correlated with premature mortality (98.3+/-42.5 d, P<0.0001). Expression analyses revealed the abundance of Pten transcript, a known miR-17-92 target, to be inversely correlated with miR-17-92 expression levels and heart size. In addition, we demonstrated through 3'-UTR luciferase assays and expression analyses that Connexin43 (Cx43) is a novel direct target of miR-19a/b and its expression is suppressed in transgenic hearts. Taken together, these data demonstrate that dysregulated expression of miR-17-92 during cardiovascular morphogenesis results in a lethal cardiomyopathy, possibly in part through direct repression of Pten and Cx43. This study highlights the importance of miR-17-92 in both normal and pathological functions of the heart, and provides a model that may serve as a useful platform to test novel antiarrhythmic therapeutics.-Danielson, L. S., Park, D. S., Rotllan, N., Chamorro-Jorganes, A., Guijarro, M. V., Fernandez-Hernando, C., Fishman, G. I., Phoon, C. K. L., Hernando, E. Cardiovascular dysregulation of miR-17-92 causes a lethal hypertrophic cardiomyopathy and arrhythmogenesis. FASEB J. 27, 1460-1467 (2013). www.fasebj.org

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据